The future of Neurocrine Biosciences'
Today Neurocrine said that the FDA would require an additional clinical trial for the two approvable lower doses of Indiplon. Based on this request for additional trials, the company hopes to resubmit an application for Indiplon "before the end of Q2 2007."
Based on Neurocrine's statements, I fully expect Indiplon to receive a class 2 six-month review from the FDA -- rather than the shorter two-month class 1 review -- because the new clinical trial data will accompany the drug's resubmission for approval. This pushes any possible Indiplon approval out until early 2008 at the soonest, assuming there are no other setbacks along the way. Unfortunately, the company did not give any timeline for the long-lasting 15 mg dose of Indiplon.
It's worth mentioning here that even with this extended timeline for Indiplon, investors shouldn't be so quick to assume that lower doses will have an easy path toward approval or reach a high level of sales. I think Neurocrine firing the company's sales force and Pfizer
I'm definitely not trying to sound like a pessimist here. Neurocrine is barely trading for above cash value and the company does have other promising drugs in the pipeline, but biotech investors have a tendency to minimize risks of a drug gaining approval. Sometimes biotech investors have nobody but themselves to blame, but other times it can be management's fault; they tend to paint a rosy picture of their drug's prospects, and thus the drug's warts only reveal themselves under an FDA panel review or drug rejection.
For more Foolish perspectives on Neurocrine:
- The FDA Tries to Put Neurocrine to Sleep
- Neurocrine Biosciences: From Bad to Worse
- Neurocrine's Tale of Woe
More from The Motley Fool
Here's Why Neurocrine Biosciences Is Soaring
Blowout quarterly results caused traders to cheer.
The 3 Best Pharmaceutical Stocks to Buy in 2017
Here's why Pfizer, Teligent, and Neurocrine Biosciences are all top pharmaceutical stocks to own this year.
Why Neurocrine Biosciences Stock Is Soaring Higher Today
The biotech struck regulatory gold with its tardive dyskinesia drug, Ingrezza.